CriticalSelective mineralocorticoid receptor antagonist×Triazole derivatives, systemic antifungals
Updated · Methodology
Mechanism
CYP3A4 is the main enzyme that metabolises eplerenone (eplerenone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and voriconazole is a strong inhibitor of this enzyme (voriconazole SmPC, European Medicines Agency, EMA). The pair has not been studied and the documents give no figures, but both voriconazole labels expect eplerenone levels to rise significantly (EMA; voriconazole prescribing information, US Food and Drug Administration, FDA). For comparison, ketoconazole, another strong CYP3A4 inhibitor, at 200 mg twice daily increased the eplerenone area under the concentration–time curve (AUC) by 441%, or 5.4-fold (AEMPS; eplerenone prescribing information, FDA). Eplerenone blocks mineralocorticoid receptors and can raise blood potassium, and the eplerenone SmPC names low blood pressure and hyperkalaemia as the most likely signs of overdose (AEMPS).
Symptoms
The main risks are hyperkalaemia and a fall in blood pressure. The eplerenone summary of product characteristics (SmPC) names them as the most likely signs of overdose and lists hyperkalaemia, dizziness, syncope, hypotension and orthostatic hypotension among adverse reactions (eplerenone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Hyperkalaemia is more likely in older people, in reduced kidney function and in diabetes (AEMPS). The US label adds proteinuria and concurrent use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, non-steroidal anti-inflammatory drugs and even moderate CYP3A inhibitors (eplerenone prescribing information, US Food and Drug Administration, FDA). The same label lists dizziness, diarrhoea, vomiting, a rapid or irregular heartbeat, leg swelling and difficulty breathing as warning signs (FDA).
Management
The combination is contraindicated. Both voriconazole labels name eplerenone among drugs that must not be combined with voriconazole. The metabolism of these drugs depends heavily on CYP3A4, and high levels are linked to serious or life-threatening reactions (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA; voriconazole prescribing information, US Food and Drug Administration, FDA). The eplerenone labels contraindicate eplerenone with strong CYP3A4 inhibitors (eplerenone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; eplerenone prescribing information, FDA), and the voriconazole labels describe voriconazole as a strong inhibitor of this enzyme (EMA; FDA). In the US eplerenone label, this contraindication applies to all patients, not only to those treated for hypertension (FDA). In Spain, eplerenone is authorised only for heart failure (AEMPS). In people taking eplerenone, check serum potassium at the start of treatment and at every dose change (AEMPS). Check potassium and creatinine within 3–7 days of starting even a moderate CYP3A inhibitor (FDA). If serum potassium reaches 6.0 mmol/L or more, stop eplerenone, and restart at 25 mg every other day once potassium falls below 5.0 mmol/L (AEMPS). Treat hypotension with supportive care and hyperkalaemia with standard treatment. Haemodialysis does not remove eplerenone (AEMPS). The documents do not say how long to wait after stopping voriconazole before starting eplerenone. The voriconazole half-life depends on the dose, about 6 hours at 200 mg, and because of non-linear kinetics it does not predict elimination (EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Vfend (voriconazole) prescribing information – CYP3A4 inhibitor, statin/immunosuppressant interactions (2020)– FDA Vfend label, Drug Interactions §7 – tacrolimus, cyclosporine, sirolimus, statins; DailyMed setid ce3ef5cf-3087-4d92-9d94-9eb8287228db
- FDA: Inspra (eplerenone) prescribing information (2018)– FDA Inspra label, Warnings §5.1 and Drug Interactions §7; DailyMed setid 1a52bedc-8e2c-4116-a296-a87770676b4a
- EMA: Ficha técnica: Voriconazol, Vfend (EU/1/02/212), secciones 4.3, 4.4 y 4.5 (2026)– EMA, SmPC Vfend 200 mg comprimidos, EU/1/02/212, texto en CIMA nº registro 02212015, consultado 11.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Eplerenona, Inspra 25 mg (nº registro 66356), secciones 4.3, 4.4 y 4.5 (2025)– AEMPS, CIMA, nº registro 66356, documento 01/2025 (fecha de revisión del texto 01/2024), secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Voriconazol (EU/1/02/212), sección 4.5 (2026)– EMA SmPC vía AEMPS CIMA, nº 02212015 (EU/1/02/212), secciones 4.2, 4.4 y 4.5, consultado 10/2026
- AEMPS: Ficha técnica: Eplerenona, Inspra 25 mg (nº registro 66356), secciones 4.1 y 4.2 (2025)– AEMPS, CIMA, nº registro 66356 (Inspra 25 mg comprimidos recubiertos con película, Viatris Healthcare), documento 01/2025, secciones 4.1, 4.2, 4.8 y 4.9